Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology

Peter Seferović, Dimitrios Farmakis*, Antoni Bayes-Genis, Tuvia Ben Gal, Michael Böhm, Ovidiu Chioncel, Roberto Ferrari, Gerasimos Filippatos, Loreena Hill, Ewa Jankowska, Mitja Lainscak, Yuri Lopatin, Lars H. Lund, Alexandre Mebazaa, Marco Metra, Brenda Moura, Giuseppe Rosano, Thomas Thum, Adriaan Voors, Andrew J.S. Coats

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Downloads (Pure)

Abstract

Knowledge on risk predictors of incident heart failure (HF) in patients with type-2 diabetes (T2D) is crucial given the frequent coexistence of the two conditions and the fact that T2D doubles the risk of incident HF. In addition, HF is increasingly being recognised as an important endpoint in trials in T2D. On the other hand, the diagnostic and prognostic performance of established CV biomarkers may be modified by the presence of T2D. The present position paper, derived by an expert panel workshop organized by the Heart Failure Association of the European Society of Cardiology, summarizes the current knowledge and gaps in evidence regarding the use of a series of different biomarkers, reflecting various pathogenic pathways, for the prediction of incident HF and CV events in patients with T2D and in those with established HF and T2D.
Original languageEnglish
JournalEuropean journal of heart failure
Early online date15 Jun 2022
DOIs
Publication statusEarly online date - 15 Jun 2022

Bibliographical note

Funding Information:
P.S.: honorarium for lectures from Servier, AstraZeneca, Respicardia, Menarini; consultancy agreement and honorarium for lecture from Boehringer Ingelheim, Novartis, Vifor Pharma and Roche Diagnostics. D.F.: lecture or consultation fees from Abbott Laboratories, Bayer, Boehringer Ingelheim, Leo, Novartis and Orion. A.B.G.: lecture honoraria or participated in advisory boards from Abbott, AstraZeneca Boehringer Ingelheim, Novartis, Roche Diagnostics, Vifor. M.B.: supported by the Deutsche Forschungsgemeinschaft (German Research Foundation; TRR219, project number 322900939) and reports personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Medtronic, Novartis, ReCor Medical, Servier, and Vifor. O.C.: grants from Servier, Vifor Novartis and fees from Boehringer Ingelheim. R.F.: research grants and personal fees from Novartis and Servier, personal fees from Merck Serono, Boehringer Ingelheim, Sunpharma, Lupin, Doc Generici, Pfizer, Spa Prodotti Antibiotici; director of Art Research and Science S.r.l (A.R.S.1). G.F.: participation in committees of trials and registries sponsored by Bayer, Boehringer Ingelheim, Medtronic, Servier, Novartis, and Vifor. E.J.: research grants and personal fees from Vifor Pharma, personal fees from Bayer, Novartis, Abbott, Boehringer Ingelheim, Pfizer, Servier, AstraZeneca, Berlin Chemie, Cardiac Dimensions, Takeda and Gedeon Richter. M.L.: personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, Bayer. L.H.L.: grants from AstraZeneca,Vifor, Boston Scientific, Boehringer Ingelheim, Novartis; consulting fees from Merck, Vifor, AstraZeneca, Bayer, Pharmacosmos, MedScape, Sanofi, Lexicon, Myokardia, Boehringer Ingelheim, Servier; speakers honoraria from Abbott, MedScape, Radcliffe, AstraZeneca, Novartis; shareholder in AnaCardio. A.M.: personal fees from Novartis, Orion, Roche, Servier, Sanofi, Otsuka, Philips, grants and personal fees from Adrenomed, Abbott; grants from 4TEEN4. M.M.: personal fees from Actelion, Amgen, AstraZeneca, Abbott Vascular, Bayer, Servier, Edwards Therapeutics, Livanova, Vifor Pharma, WindTree Therapeutics, as member of Trials' Committees or advisory boards or for speeches at sponsored meetings in the last 3 years. B.M.: advisory or speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Ely Lilly, Servier, Novartis, Vifor Pharma. T.T.: founder and shareholder of Cardior Pharmaceuticals GmbH; speaker fees from Novo Nordisk, Boehringer Ingelheim, Sanofi‐Genzyme, Takeda, Amicus Therapeutis, KSLINK. A.V.: research support and/or consulting fees from Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cytokinetics, Merck, MyoKardia, Novartis, NovoNordisk, and Roche Diagnostics. A.J.S.C.: honoraria and/or lecture fees from Astra Zeneca, Boehringer Ingelheim, Menarini, Novartis, Servier, Vifor, Abbott, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Impulse Dynamics, Respicardia, Viatris, outside of this work in the last 3 years. All other authors have nothing to disclose. Conflict of interest:

Publisher Copyright:
© 2022 European Society of Cardiology.

Keywords

  • Cardiology and Cardiovascular Medicine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: A position statement from the Heart Failure Association of the European Society of Cardiology: a position statement from the Heart Failure Association of the European Society of Cardiology'. Together they form a unique fingerprint.

Cite this